Head-to-head · Cost-Efficiency Index
NewSelf vs Henry Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NewSelf
Budget shoppers who want a verified all-50 program and one of the lowest disclosed tirzepatide prices in the value tier.
Visit NewSelfHenry Meds
People who want a simple, well-known flat-fee program and will pay a premium for the brand.
Visit Henry MedsThe verdict
NewSelf takes it, leading the Cost-Efficiency Index 87 to 81. $100 semaglutide and $144 tirzepatide, nationwide and LegitScript-verified — near-identical value to the cheapest verified names, with the tirzepatide price a hair lower than most. Henry Meds still earns a B− — People who want a simple, well-known flat-fee program and will pay a premium for the brand.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs NewSelf.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NewSelf | Henry Meds |
|---|---|---|
| Cost-Efficiency Index | 87/100 | 81/100 |
| Semaglutide / mo | $100/mo | $249/mo |
| Tirzepatide / mo | $144/mo | $349/mo |
| Semaglutide / yr (modeled) | $1,200 | $2,988 |
| Tirzepatide / yr (modeled) | $1,728 | $4,188 |
| Coverage | All 50 states | Multi-state |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #6 | #23 |
NewSelf
87/100Where the value is
- $100 semaglutide / $144 tirzepatide — one of the cheapest verified combined prices on the board
- Nationwide all-50 coverage with both molecules published up front
- LegitScript-certified pharmacy behind the low price
The tradeoffs
- Compounded only — no brand-name or oral option
- Newer consumer brand with a thin public track record
Henry Meds
81/100Where the value is
- Simple, transparent flat-fee model that's easy to model
- Well-established brand
- Both molecules disclosed
The tradeoffs
- Higher per-month cost than many newer entrants weakens value
- Compounded only
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.